Pharmaniaga Bhd emerged as the most actively traded stock on Bursa Malaysia, with its shares rising nearly 10 per cent following the pharmaceutical company’s exit from Practice Note 17 (PN17) today.
At the time of writing, the stock was holding at its intraday high of 28 sen, up 9.8 per cent or 2.5 sen, with more than 114 million shares traded.
Earlier, it opened two sen or 7.84 per cent higher at 27.5 sen, and has traded between 26 sen and 28 sen so far. At current price, the company is valued at RM1.83 billion.
Year to date, Pharmaniaga’s share price is unchanged at 28 sen, with a trading range of between 24 sen and 32.5 sen.
Pharmaniaga was classified as a PN17 company on Feb 27, 2023, and has since undertaken a series of regularisation measures, supported by steady improvements in operational performance.
Since the quarter ended March 31, 2024, the group has posted eight consecutive profitable quarters, culminating in a net profit of RM50.7 million for the financial year ended Dec 31, 2025, up 30.5 per cent from the adjusted net profit of RM38.8 million in 2024.
Managing director Datuk Zulkifli Jafar said the achievement reflects the resilience, discipline and collective commitment demonstrated across the organisation during a challenging period.
With the PN17 status lifted, he said the company will now focus on driving long-term growth and expanding its strategic capabilities across the healthcare value chain.
Chinese 
English